Navigation Links
According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
Date:3/18/2013

BURLINGTON, Mass., March 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its recent market entry, Johnson & Johnson/Janssen Biotech/Janssen Cilag's Zytiga has heavily penetrated surveyed EU5 (France, Germany, Italy, Spain and the United Kingdom) oncologists' second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients who have received prior treatment with docetaxel. Uptake of Zytiga is especially high in France and the United Kingdom, where, on average, approximately half of respondents' second-line patients are prescribed Zytiga.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Among respondents in most countries, Sanofi's Jevtana is more commonly used in the third-line than the second-line setting, suggesting that second-to-market Zytiga is displacing Jevtana to later-line mCRPC. In support of this finding, most of those surveyed in all countries indicate that the recent launch of Zytiga will influence a shift in prescribing of Jevtana toward later-line mCRPC treatment in the next 12 months.

The new European Physician & Payer Forum report entitled The Dynamic Prostate Cancer Landscape: How Will European Payer and Prescriber Attitudes Shape This Competitive Market? finds that more than one-third of respondents in Germany and Spain believe Zytiga's launch will significantly influence a shift in Jevtana's prescribing, while almost one-quarter of those in Italy agree. Zytiga's more favorable side-effect profile, convenient oral administration, and mechanism of action likely explain why such a substantial percentage of physicians expect this trend. At the end of 2015, despite the anticipated approval of three new therapies—Medivation/Astellas Pharma's Xtandi, Algeta/Bayer HealthCare's radium-223, and Takeda/Millennium's orteronel—Zytiga will maintain its position as the favored second-line mCRPC therapy among surveyed EU5 physicians.

This report also finds that, in addition to robust efficacy, therapeutic innovation and demonstrable downstream cost savings are key market access levers that will encourage EU5 payers to think beyond an emerging agent's proposed price tag. Pharmaceutical innovation is key to reimbursement decision making in Italy and Spain, and, in the former, inclusion on AIFA's innovative drugs list ensures funding across regions.

"Savings in hospitalization and supportive care costs, as well as the societal benefits of improving quality of life, will help encourage uptake within countries following admission to reimbursement," said Decision Resources Senior Director Rachel Webster , Ph.D. "Costs associated with management of Jevtana's side effects may well have contributed to NICE's decision on its lack of cost-effectiveness. Furthermore, the United Kingdom's value-based pricing system, set to be implemented at the end of this year, will pave the way for consideration of wider societal benefits and associated cost savings, and the principles of this concept are increasingly evident across the EU5."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Handwritten Scripts Still Outpace E-Prescribing by More than 60 Percent, According to New Data
2. Food Recalls Hit Two-Year High in Fourth Quarter of 2012, According to Latest ExpertRECALL Index
3. Life Sciences Venture Capital Funding Drops 14% During 2012, According To The MoneyTree Report
4. Affluence, an Aging Population, and Anticipated Rx-to-OTC Switches Boost a Healthy $32 Billion OTC Market in China, According to Kline
5. Food Recalls Rise to Four a Day in Third Quarter, Reaching Highest Level of Activity in Eight Quarters, According to the ExpertRECALL Index
6. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
7. European Market for Dental Instruments Surpasses $652 Million, According to New Market Research
8. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
9. Over 123 Million Medical Device Units Recalled in Second Quarter of 2012, Reaching an Eight-Quarter High, According to the ExpertRECALL Index
10. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
11. Vaginal Mesh Lawsuits Pick Up Momentum, According To Pulaski & Middleman, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)... 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" ... offer shares of common stock in an underwritten public ... with the Securities and Exchange Commission (the "SEC"). The ... there can be no assurance as to whether or ... the actual size or terms of the offering. Cryoport ...
(Date:3/27/2017)... Calif. , March 27, 2017  Sanderling ... acquired by Ethicon, a division of Johnson & ... System for the treatment of gastro-esophageal reflux disease ... sphincter augmentation (MSA) technology and the procedure is ... centers. Torax Medical was founded by ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business ... has begun to serve as its new executive director. Mr. Still was selected through ... Committee. , “Bob, as he is known to our members, has been a ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With less than ... acne, access to quality care can be limited while the desire to conquer breakouts ... customized prescription acne care for every customer online, today released its inaugural survey on ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... patients desire to achieve the “perfect smile.” The National Association of Dental Laboratories ... as what dentists should be aware of when utilizing dental laboratories and technicians ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in mind, Patten Seed ... The seed processing plant opened in Marshallville in 2006, and a bagging and shipping ... opportunity for transition of Patten Seed operations to the Middle Georgia location from their ...
(Date:3/28/2017)... ... ... that reveals the mystery of Kevin’s purpose. “A Prophets Bones” is the creation of published ... him that he had neglected to do, but this was from God and there was ... would have felt themselves to be special and better than others due to the fact ...
Breaking Medicine News(10 mins):